Recombinant Human IL-17A
Interleukin-17A (IL-17A), also known as CTLA-8, is a 15-20 kDa glycosylated cytokine that plays an important role in anti-microbial and chronic inflammation. The six IL-17 cytokines (IL-17A-F) are encoded by separate genes but adopt a conserved cystine knot fold [1, 2]. Mature human IL-17A shares 60% amino acid sequence identity with mouse and rat IL-17A [3, 4]. IL-17A is secreted by Th17 cells, gamma /δ T cells, iNKT cells, NK cells, LTi cells, neutrophils, and intestinal Paneth cells [2]. It forms disulfide-linked homodimers as well as disulfide-linked heterodimers with IL-17F [5, 6]. IL-17A exerts its effects through the transmembrane IL-17RA in complex with IL-17RC or IL-17RD [7, 8]. Both IL-17RA and IL-17RC are required for responsiveness to heterodimeric IL-17A/F [7]. IL-17A promotes protective mucosal and epidermal inflammation in response to microbial infection [9-12]. It induces chemokine production, neutrophil influx, and the production of antibacterial peptides [9-11]. IL-17A/F likewise induces neutrophil migration, but IL-17F does not [11]. IL-17A additionally enhances the production of inflammatory mediators by rheumatoid synovial fibroblasts and contributes to TNF-alpha induced shock [4, 13]. In contrast, it can protect against the progression of colitis by limiting chronic inflammation [12]. IL-17A has been shown to exert either tumorigenic or anti-tumor effects [14, 15].
Reference
[1]. Gaffen, S.L. (2009) Nat. Rev. Immunol. 9:556.
[2]. Cua, D.J. and C.M. Tato (2010) Nat. Rev. Immunol. 10:479.
[3]. Yao, Z. et al. (1995) J. Immunol. 155:5483.
[4]. Fossiez, F. et al. (1996) J. Exp. Med. 183:2593.
[5]. Chang, S.H. and C. Dong (2007) Cell Res. 17:435.
[6]. Wright, J.F. et al. (2007) J. Biol. Chem. 282:13447.
[7]. Wright, J.F. et al. (2008) J. Immunol. 181:2799.
[8]. Rong, Z. et al. (2009) Cell Res. 19:208.
[9]. Cho, J.S. et al. (2010) J. Clin. Invest. 120:1762.
[10]. Liang, S.C. et al. (2006) J. Exp. Med. 203:2271.
[11]. Liang, S.C. et al. (2007) J. Immunol. 179:7791.
[12]. O’Connor Jr., W. et al. (2009) Nat. Immunol. 10:603.
[13]. Takahashi, N. et al. (2008) J. Exp. Med. 205:1755.
[14]. Wang, L. et al. (2009) J. Exp. Med. 206:1457.
[15]. Kryczek, I. et al. (2009) Blood 114:357.
|
Accession # |
Q16552 |
|
Alternate Names |
Human IL17A; hIL-17A, recombinant IL17A, interleukin 17A |
|
Source |
Human embryonic kidney cell, HEK293-derived human IL17A protein |
|
Protein sequence |
Gly24-Ala155 |
|
M.Wt |
15.1 kDa (Monomer) |
|
Appearance |
Solution protein. |
|
Stability & Storage |
Avoid repeated freeze-thaw cycles. It is recommended that the protein be aliquoted for optimal storage. 12 months from date of receipt, -20 to -70 °C as supplied. |
|
Concentration |
0. 2 mg/mL |
|
Formulation |
Dissolved in sterile PBS buffer. |
|
Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. This solution can be diluted into other aqueous buffers. |
|
Biological Activity |
Measured by its ability to induce IL-6 secretion by NIH-3T3 mouse embryonic fibroblast cells. The ED50 for this effect is 1.0-7.5 ng/mL. |
|
Shipping Condition |
Shipping with dry ice. |
|
Handling |
Centrifuge the vial prior to opening. |
|
Usage |
For Research Use Only! Not to be used in humans. |
Quality Control & DataSheet
- View current batch:
-
Purity > 95%, determined by SDS-PAGE.
- Datasheet
Endotoxin: <0.010 EU per 1 ug of the protein by the LAL method.